<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03287778</url>
  </required_header>
  <id_info>
    <org_study_id>17-1500</org_study_id>
    <nct_id>NCT03287778</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia</brief_title>
  <official_title>Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation of Hope, North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Tardive dyskinesia (TD) is a involuntary movement disorder that can occur following&#xD;
      long term treatment with antipsychotic medications and for which few treatment options exist.&#xD;
      This study will test the efficacy of pyridoxine (also known as vitamin B6) for TD. This will&#xD;
      be an 8 week double-blind, placebo-controlled, randomized trial measuring the effect of&#xD;
      pyridoxine 400 mg/day on the severity of involuntary muscle movements in people who meet&#xD;
      Schooler-Kane criteria for TD.&#xD;
&#xD;
      Participants: Approximately 50 subjects will be recruited from the UNC Schizophrenia&#xD;
      Treatment and Evaluation Program (STEP) and other local psychiatric clinics.&#xD;
&#xD;
      Procedures (methods): Symptoms of TD will be assessed using the Abnormal Involuntary Movement&#xD;
      Scale (AIMS). Pharmacological Intervention: All participants who meet entry criteria will be&#xD;
      randomized to one of two treatment groups: pyridoxine or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overview of Procedures: All procedures will be conducted at either the University of North&#xD;
      Carolina Hospitals in Chapel Hill, or at the North Carolina Psychiatric Research Center&#xD;
      (NCPRC), a specialized program of the University of North Carolina Center for Excellence in&#xD;
      Community Mental Health, in Raleigh.&#xD;
&#xD;
      Screening: During the initial clinic visit and after providing written informed consent,&#xD;
      prospective subjects' psychiatric and medical histories will be reviewed, physical exams&#xD;
      conducted, demographics and vital signs obtained, and blood and urine collected. The&#xD;
      Structured Clinical Interview for DSM-V, the Columbia Suicide Severity Rating Scale (C-SSRS),&#xD;
      and the Clinical Global Impressions-Severity (CGI-S) will be used to evaluate&#xD;
      psychopathology. Involuntary muscle movements will be assessed using the Abnormal Involuntary&#xD;
      Movement Scale (AIMS). The AIMS exam will be video recorded. Other neurological side effects&#xD;
      of antipsychotic medications will be assessed using the Barnes Akathisia Scale (BARS) and&#xD;
      Simpson-Angus Scale (SAS).&#xD;
&#xD;
      The baseline visit will be scheduled within 28 days of the screening visit. Vital signs and&#xD;
      weight will be measured. A blood test to measure baseline pyridoxine level will be collected.&#xD;
      A battery of assessments will be administered including the Clinical Global&#xD;
      Impressions-Severity (CGI-S), the Alcohol Use Scale, Substance Use Scale, Brief Psychiatric&#xD;
      Rating Scale (BPRS), Columbia Suicide Severity Rating Scale (C-SSRS), AIMS (video recorded),&#xD;
      BARS, and SAS.&#xD;
&#xD;
      At the completion of the baseline visit, subjects who continue to meet study inclusion&#xD;
      criteria will be randomized to one of two treatment groups (pyridoxine or placebo). Subjects&#xD;
      assigned to the pyridoxine group will receive 200 mg per day for one week and then 400 mg per&#xD;
      day, as tolerated, for the remainder of the study. Subjects assigned to the placebo group&#xD;
      will receive matching placebo capsules.&#xD;
&#xD;
      After study enrollment, subjects will be scheduled for Week 1 and Week 2 study visits. The&#xD;
      purpose of these visits will be to assess medication management (i.e., adverse events/side&#xD;
      effects, adherence), collect vital signs, assess current psychiatric status, and assess&#xD;
      neurological symptoms using the AIMS (video recorded), BARS, and SAS. The CGI-S will be&#xD;
      performed at both Week 1 and Week 2, however, the C-SSRS will be completed at Week 2 only.&#xD;
&#xD;
      Study visit at Week 4 and end-of-study visit at Week 8 will be similar to Week 2, with the&#xD;
      addition of the BPRS, Substance Use Scale and Alcohol Use Questionnaire. A blood test to&#xD;
      measure pyridoxine levels will also be collected during these visits. Study drug is&#xD;
      discontinued at the Week 8 visit.&#xD;
&#xD;
      A follow-up visit at Week 10, two weeks after stopping the treatment, will consist of&#xD;
      assessing for adverse events/side effects, collecting vital signs, administrating the CGI-S&#xD;
      and C-SSRS, and performing the AIMS (video recorded), BARS, and SAS. The follow-up visit will&#xD;
      help determine whether the potential benefits of pyridoxine for TD may continue after&#xD;
      treatment is discontinued.&#xD;
&#xD;
      Vital signs, adverse events, and side effects will be obtained at all in-person study visits.&#xD;
      Blood collection and laboratory testing will be done at Screening, Baseline, Week 4, and Week&#xD;
      8 .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Difference in AIMS scores</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Mean difference in Abnormal Involuntary Movement Scale (AIMS) total scores in participants assigned to pyridoxine and participants assigned to placebo from baseline to Week 8.&#xD;
The severity of TD symptoms is assessed by the Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1 through 7). The AIMS total dyskinesia score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Difference in Barnes Akathisia Rating Scale Scores</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Mean difference in Barnes Akathisia Rating Scale (BARS) scores in participants assigned to pyridoxine and participants assigned to placebo from baseline to Week 8.&#xD;
Barnes Akathisia Scale (BARS) is a rating scale that is administered by physicians to assess the severity of drug-induced akathisia, which is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion. The following subcategories are scored: objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness and are rated on a 4-point scale from 0 - 3. In addition, the global clinical assessment of akathisia uses a 6-point scale ranging from 0 - 5 (absent to severe). The total score ranges from 0 to 14 with a higher score indicating increased severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Difference in Simpson Angus Scale Scores</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Mean difference in Simpson Angus Scale (SAS) scores in participants assigned to pyridoxine and participants assigned to placebo from baseline to Week 8.&#xD;
The Simpson-Angus Scale (SAS) is a 10-item testing instrument used to evaluate drug-related extrapyramidal syndromes. The following items are included in the SAS: gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella reflex, tremor, and salivation. Total score ranges from 0 to 40 with a higher score indicating increased severity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Tardive Dyskinesia</condition>
  <condition>Antipsychotic Agents</condition>
  <arm_group>
    <arm_group_label>Pyridoxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pyridoxine will be administered in dosages of 200 mg with a maximum dose of 400 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebos will be administered for each active drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>Max dose of 400 mg QD PO</description>
    <arm_group_label>Pyridoxine</arm_group_label>
    <other_name>Vitamin B6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebos will be administered.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet Schooler - Kane criteria for TD (at least one muscle group is rated at &quot;moderate&quot;&#xD;
             severity or at least two muscle groups are rated at &quot;mild&quot; severity).&#xD;
&#xD;
          -  Subjects must have &gt; or equal to 3 months of antipsychotic exposure.&#xD;
&#xD;
          -  Other causes of involuntary movements have been ruled out.&#xD;
&#xD;
          -  Psychiatrically stable as defined by outpatient status for &gt; or equal to 2 months.&#xD;
&#xD;
          -  No change in dopamine antagonist agent or dose for &gt; or equal to 2 months or change in&#xD;
             other prescribed medications for &gt; or equal to 1 month prior to enrollment&#xD;
&#xD;
          -  Patients must be 18-80 years of age.&#xD;
&#xD;
          -  Patients must demonstrate adequate decisional capacity to make a choice about&#xD;
             participating in this research study and must provide written informed consent to&#xD;
             participate.&#xD;
&#xD;
          -  Women who can become pregnant must be using an adequate method of contraception to&#xD;
             avoid pregnancy throughout the study. Acceptable methods include oral, injectable or&#xD;
             implanted contraceptives, intrauterine devices or barrier methods such as condoms,&#xD;
             diaphragm and spermicides. Women who can become pregnant must have a negative serum&#xD;
             beta human chorionic gonadotropin (Î²-HCG) pregnancy test at the Screening Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inpatient status&#xD;
&#xD;
          -  Clinical Global Impression Severity (CGI-S) score &gt; or equal to 6.&#xD;
&#xD;
          -  Evidence of any medical condition(s) that could confound the presence of TD.&#xD;
&#xD;
          -  Currently taking more than 2 antipsychotic medications.&#xD;
&#xD;
          -  Currently taking levodopa.&#xD;
&#xD;
          -  Current or prior treatment with valbenazine or deutetrabenazine within the past 3&#xD;
             months.&#xD;
&#xD;
          -  Current or prior treatment with pyridoxine within the past 3 months.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Alcohol use disorder as determined by the SCID within the past month.&#xD;
&#xD;
          -  Substance use disorder (except caffeine and nicotine) as determined by the SCID within&#xD;
             the past month.&#xD;
&#xD;
          -  No serious and unstable medical condition(s) in the judgment of the investigator.&#xD;
&#xD;
          -  DSM-V diagnosis of intellectual disability, moderate or greater severity; or diagnosis&#xD;
             of major neurocognitive disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars F Jarskog, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars F Jarskog, MD</last_name>
    <phone>919-843-7683</phone>
    <email>lars_jarskog@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars F Jarskog, MD</last_name>
      <phone>919-843-7683</phone>
      <email>lars_jarskog@med.unc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lerner V, Miodownik C, Kaptsan A, Cohen H, Matar M, Loewenthal U, Kotler M. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001 Sep;158(9):1511-4.</citation>
    <PMID>11532741</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 15, 2017</study_first_submitted>
  <study_first_submitted_qc>September 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2017</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyridoxine</keyword>
  <keyword>Vitamin B6</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Involuntary Movements</keyword>
  <keyword>Movement Disorder</keyword>
  <keyword>Dyskinesias</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Schizophrenia Spectrum and Other Psychotic Disorders</keyword>
  <keyword>Signs and Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyskinesias</mesh_term>
    <mesh_term>Tardive Dyskinesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

